Abstract 2251P
Background
Radiotherapy-induced breast angiosarcoma (RIBAS) is a very rare late complication of radiotherapy (RT) in breast cancer. The incidence of RIBAS is expected to increase in the next few years, following the widespread adoption of breast-sparing surgery in combination with adjuvant treatment. To date, no actionable gene mutations are described, and data availability is very limited. Leveraging a multicentric retrospective cohort, we assessed the genomic features of a collected case series of patients affected by both sporadic (sBAS) and RT-induced form of angiosarcoma.
Methods
We retrospectively collected FFPE tumor and germline samples, obtained by surgery or biopsy. Samples were subjected to whole exome sequencing (WES, NovaSeq 6000 Illumina). Raw data were analyzed using the open source nf-Sarek pipeline. Mutation calls were identified using Mutect2, Strelka2 and independently validated using the Dragen platformTM. Variants were annotated using COSMIC, OncoKB, ClinVar in conjunction with functional predictors, such as FATHMM, SIFT and Polyphen. Copy number aberrations were assessed using CNVkit.
Results
We collected matched tumor-normal pairs from 43 cases (30 RIBAS, 8 sBAS, 5 with no clinical annotation). All the patients were female, the overall median age at diagnosis was 68.8 years (IQR: 52.1 – 75.1), 69.8 (IQR: 61.4 – 76) for RIBAS and 41.2 (IQR: 28.6 – 53.7) for sBAS patients. WES was performed on 18 cases, 12 RIBAS, and 6 sBAS. We identified two PIK3CA hotspot mutations (p.E542V, p.V344M) in RIBAS only, but not in sBAS. One TP53 mutation was identified in one sBAS sample. The most recurrent copy number aberration was MYC amplification (N = 5), exclusively found in RIBAS. Over-representation analysis showed enrichment in the NOTCH signaling, and E2F-targets pathways.
Conclusions
The genomic repertoire of RIBAS and sBAS is heterogenous, and we identified recurrent potential clinically actionable markers. We are currently expanding our analyses to 26 novel cases, including those reported in the Angiosarcoma Project. Germline calls are being assessed. To our knowledge, our study represents the largest effort to unveil the molecular landscape of RIBAS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Alleanza Contro il Cancro - Ricerca Corrente Reti 2019, 2021 e 2022.
Disclosure
A. Vingiani: Financial Interests, Other, Honoraria: Roche, Lilly. M. Lambertini: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Lilly, Novartis, Pfizer, Exact Sciences, MSD, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: Takeda, Sandoz, Ipsen, Libbs, Knight, Daiichi Sankyo, Lilly, Pfizer, Novartis, Roche; Financial Interests, Personal, Other, Travel grant to attend ASCO 2022: Gilead; Financial Interests, Institutional, Coordinating PI, 2-year research grant paid to my Institution: Gilead. G. Pruneri: Financial Interests, Other: Novartis, Roche, Lilly, Exact Science. L. Mazzarella: Financial Interests, Advisory Board: Thetis Inc. G. Zoppoli: Financial Interests, Stocks or ownership: Immnomica srl.; Financial Interests, Invited Speaker: Novartis; Non-Financial Interests, Product Samples: ThermoFisher Scientific; Non-Financial Interests, Personal, Other, Travel Grant: Novartis, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07
2162P - Can artificial intelligence provide accurate and reliable answers to cancer patients' questions? Comparison of chatbots based on the ESMO Patient Guide about cancer pain
Presenter: Kadriye Bir Yucel
Session: Poster session 07
2163P - Supportive care in French community pharmacies: OncoPharma certification
Presenter: Jérôme Sicard
Session: Poster session 07
2164P - The impact of cancer patients’ face masks on oxygenation and Co2 retention during treatment
Presenter: Mert Sahin
Session: Poster session 07
2165P - A French overview of electronic patient-reported outcomes use in 2022
Presenter: Melina Hocine
Session: Poster session 07
2166P - Long-term consequences of SARS-CoV-2 infection in cancer patients
Presenter: Yana Debie
Session: Poster session 07
2167P - Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study
Presenter: Michael Mark
Session: Poster session 07
2168P - At-home infusion of immunotherapy for patients with solid tumors: First results from a single-centre program
Presenter: Javier Marco Hernández
Session: Poster session 07
2169P - Immunotherapy-based treatment in elderly cancer patients: A real-world multicenter study
Presenter: Mengye He
Session: Poster session 07
2171P - Incidence of adverse events in patients treated with a combination of immune checkpoint blockers and chemotherapy: A real life cohort
Presenter: Layal Rached
Session: Poster session 07